Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.

Wollenberg, A; Barbarot, S; Bieber, T; Christen-Zaech, S; Deleuran, M; Fink-Wagner, A; Gieler, U; Girolomoni, G; Lau, S; Muraro, A; Czarnecka-Operacz, M; Schäfer, T; Schmid-Grendelmeier, P; Simon, Dagmar; Szalai, Z; Szepietowski, J C; Taïeb, A; Torrelo, A; Werfel, T and Ring, J (2018). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. Journal of the European Academy of Dermatology and Venereology, 32(6), pp. 850-878. Blackwell 10.1111/jdv.14888

[img] Text
Wollenberg_et_al-2018-Journal_of_the_European_Academy_of_Dermatology_and_Venereology_2.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (311kB) | Request a copy

This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic reviews and published studies into account. This second part of the guideline covers antimicrobial therapy, systemic treatment, allergen-specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions, whereas the first part covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy. Management of AE must consider the individual clinical variability of the disease. Systemic immunosuppressive treatment with cyclosporine, methotrexate, azathioprine and mycophenolic acid is established option for severe refractory cases, and widely available. Biologicals targeting the T helper 2 pathway such as dupilumab may be a safe and effective, disease-modifying alternative when available. Oral drugs such as JAK inhibitors and histamine 4 receptor antagonists are in development. Microbial colonization and superinfection may cause disease exacerbation and can require additional antimicrobial treatment. Allergen-specific immunotherapy with aeroallergens may be considered in selected cases. Psychosomatic counselling is recommended especially in stress-induced exacerbations. Therapeutic patient education ('Eczema school') is recommended for children and adult patients. General measures, basic emollient treatment, bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy have been addressed in the first part of the guideline.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Simon, Dagmar

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0926-9959

Publisher:

Blackwell

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

11 Feb 2019 14:16

Last Modified:

11 Feb 2019 14:16

Publisher DOI:

10.1111/jdv.14888

PubMed ID:

29878606

BORIS DOI:

10.7892/boris.123355

URI:

https://boris.unibe.ch/id/eprint/123355

Actions (login required)

Edit item Edit item
Provide Feedback